| (Values in U.S. Thousands) | Dec, 2025 | Jun, 2025 | Dec, 2024 | Jun, 2024 | Dec, 2023 |
| Sales | 2,320 | 270 | 1,040 | 0 | 0 |
| Sales Growth | +759.26% | -74.04% | unch | unch | unch |
| Net Income | -17,230 | -10,660 | -7,500 | 0 | 0 |
| Net Income Growth | -61.63% | -42.13% | unch | unch | unch |
Inventiva S.A. ADR (IVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Inventiva S.A. is a clinical-stage biopharmaceutical company. It is focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Inventiva S.A. is based in Daix, France.
Fiscal Year End Date: 12/31